Windlas Biotech Limited

Windlas Biotech Limited (WINDLAS) is a micro-cap Healthcare company valued at ₹1,944 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Windlas Biotech Limited last traded at ₹916, modestly down 0.81% on the day.

Recent developments

On 2026-07-16, the company announced a dividend of ₹6.30 per share, with the ex-date set for that day. Domestic institutional holding decreased by 2.60 percentage points in the quarter, ending at 7.24%.

Financial performance

The company's annual revenue rose 19.0% to ₹904 crore, while annual net profit increased 9.0% to ₹66 crore. The latest quarter saw revenue grow 18.1% year-on-year to ₹248 crore, but net profit remained flat at ₹18 crore compared to the same quarter a year earlier.

Valuation multiples

The stock trades at 29.0 times earnings, broadly in line with the Healthcare median of 32.0, 3.97 times book value. It yields 0.6%.

Things to watch

The net profit margin narrowed by 0.7 percentage points to 7.4%, and the latest quarter's net profit declined slightly by -0.1% year-on-year. The stock is 22.4% below its 52-week high, and domestic institutional holding fell to 7.24%.

Where it stands

Windlas Biotech Ltd has shown strong revenue growth over the past five years, with a 16.1% annualized increase, but its net profit margin has declined. The stock is currently 22.4% below its 52-week high, and domestic institutional holding has dropped to 7.24%.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.